Board of Directors

Dr. Goddard has served as the chairman of our board of directors since August 2003 and was appointed our chief executive officer in April 2005. From March 2000 and August 2005, Dr. Goddard served as chairman and part-time executive of several companies including A.P. Pharma, Inc., a pharmaceutical company, and XenoPort, Inc., a biopharmaceutical company. From October 1998 until March 2000, he was chief executive officer of Elan Pharmaceuticals, Inc., the largest division of Elan Corporation plc, a biotechnology company. He was chief executive officer of Neurex Corporation, a biotechnology company, from February 1991 until October 1998 when the company was acquired by Elan Corporation plc. Prior to 1991, Dr. Goddard held various senior management positions at SmithKline Beecham plc, a pharmaceutical company, including senior vice president strategic marketing and senior vice president Far East region. He obtained his doctorate degree from St. Mary's Hospital, London, in the area of etiology and pathophysiology of colon cancer. Dr. Goddard remains on the board of directors of A.P. Pharma, Inc., Adolor Corporation, a biopharmaceutical company, and Onyx Pharmaceuticals, Inc., a biopharmaceutical company.

Mr. Beier has served as a member of our board of directors since August 2008. Mr. Beier is currently senior vice president of global government and corporate affairs for Amgen Inc, one of the world's leading biotechnology companies. Mr. Beier is responsible for global health care issues, health economics and outcomes research, corporate communications and philanthropy, and government affairs at the United States federal and state levels as well as with international governmental entities and organizations. Prior to joining Amgen, he was a partner in the international law firm of Hogan & Hartson, and was vice president of government affairs and public policy for Genentech Inc. Mr. Beier's extensive government experience includes serving as chief domestic policy advisor to Vice President Al Gore and as staff counsel in the U.S. House of Representatives. He received a B.A. from Colgate University and his J.D. from Albany Law School.

Dr. Ekman has served as a member of our board of directors since November 2003. He recently served as executive vice president and president of global research and development of Elan Pharmaceuticals for seven years. Prior to joining Elan, Dr. Ekman served as executive vice president, R&D, at Schwarz Pharma AG, a pharmaceutical company. Dr. Ekman has also served in a variety of senior scientific and clinical roles at Pharmacia Corp., which was acquired by Pfizer, Inc., a pharmaceutical company, for 14 years. Dr. Ekman is a board certified surgeon with a Ph.D. in experimental biology and has held several clinical and academic positions in both the United States and Europe. He obtained his doctorate degree and doctorate of medicine degree from the University of Gothenburg, Sweden. Dr. Ekman also serves on the board of directors at Elan Pharmaceuticals, Amarin Corp., InterMune, Inc., and Cebix, Inc.

Mr. Leonard has served as a member of our board of directors since September 2005. Since August 2005, Mr. Leonard has served as president and chief executive officer of Kythera Biopharmaceuticals, a biopharmaceutical company. From October 1991 to November 2004, Mr. Leonard held various positions with Amgen, Inc., a biopharmaceutical company, and its affiliates, most recently as senior vice president and general manager of Amgen Europe. Mr. Leonard holds a master of business administration from The Anderson School of Management, University of California, Los Angeles, a master of science in mechanical engineering from University of California, Berkeley, a bachelor of arts in history from University of Maryland, College Park, and a bachelor of science in engineering from University of California, Los Angeles.

Mr. Simon has served as a member of our board of directors since June 2002. In February 2005, Mr. Simon co-founded Clarus Ventures, LLC, a venture capital firm focused on life sciences companies. Mr. Simon has been a general partner of MPM BioVentures III, a healthcare venture capital fund, since October 2001. From April 2000 to July 2001, Mr. Simon was chief executive officer and founder of Collabra Pharma, Inc., a pharmaceutical company. Mr. Simon served in various management positions at Genentech, Inc., including its vice president of business and corporate development. Mr. Simon is currently on the board of directors of Sientra, Inc., and several pharmaceutical companies: Barrier Therapeutics, Inc., Neosil, Inc., QuatRx Pharmaceuticals Company, Pearl Therapeutics, Inc., Poniard Pharmaceuticals, Inc., and Verus Pharmaceuticals, Inc. He is also on the advisory council of the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco. Mr. Simon received a bachelor of sciences degree in microbiology from the University of Maryland and a masters in business administration in marketing from Loyola College.

Mr. Sekhri has served as a member of our board of directors since September 2004. Since January 2009, Mr. Sekhri has served as head of TPG Biotech, a financial services institution. From December 2004 to December 2008, Mr. Sekhri served as president and chief executive officer of Cerimon Pharmaceuticals, Inc., a biopharmaceutical company. Prior to founding Cerimon, from October 2003 to December 2004, Mr. Sekhri was president and chief business officer of ARIAD Pharmaceuticals, Inc., an oncology company. From December 2002 to September 2003, Mr. Sekhri was a partner at the Sprout Group, a venture capital affiliate of Credit Suisse, a financial services institution. From August 1999 to January 2003, Mr. Sekhri held various positions with Novartis Pharma AG, a pharmaceutical company, most recently as its senior vice president and head of global search and evaluation. Mr. Sekhri received his M.Sc. and B.Sc. from the University of Maryland, School of Medicine. Mr. Sekhri also serves on the board of directors at A.P.T. Pharmaceuticals, KAI Pharmaceuticals, and the Cancer Research Institute. He is also a member of the Advisory Board for the BioExec Institute, Inc. and an advisor to the Brookings Global Health Financing Initiative.

Mr. Rosenman has served as a member of our board of directors since January 2006. Since June 2001, Mr. Rosenman has served as the senior vice president of finance and chief financial officer of Gen-Probe Incorporated, a company that produces products for the clinical laboratory and blood screening. Mr. Rosenman received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania. Mr. Rosenman serves on the board of directors of Infinity Pharmaceuticals, Inc., a biopharmaceuticals company.